202 related articles for article (PubMed ID: 28835699)
21. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
Oh HN; Kwak AW; Lee MH; Kim E; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
Phytomedicine; 2021 Jan; 80():153355. PubMed ID: 33039730
[TBL] [Abstract][Full Text] [Related]
22. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
[TBL] [Abstract][Full Text] [Related]
23. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Wiesweg M; Herold T; Metzenmacher M; Eberhardt WE; Reis H; Darwiche K; Aigner C; Stuschke M; Herrmann K; Nensa F; Schildhaus HU; Schuler M
Lung Cancer; 2020 Jan; 139():165-168. PubMed ID: 31809977
[TBL] [Abstract][Full Text] [Related]
24. Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
Wei TT; Lin YC; Lin PH; Shih JY; Chou CW; Huang WJ; Yang YC; Hsiao PW; Chen CC
Oncotarget; 2015 May; 6(14):12481-92. PubMed ID: 25980579
[TBL] [Abstract][Full Text] [Related]
25. Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.
Han S; Li X; Gan Y; Li W
Biomed Res Int; 2022; 2022():5687832. PubMed ID: 35309168
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
27. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
Walsh AM; Lazzara MJ
Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
29. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
Thiagarajan PS; Wu X; Zhang W; Shi I; Bagai R; Leahy P; Feng Y; Veigl M; Lindner D; Danielpour D; Yin L; Rosell R; Bivona TG; Zhang Z; Ma PC
Oncotarget; 2016 Dec; 7(50):82013-82027. PubMed ID: 27852038
[TBL] [Abstract][Full Text] [Related]
30. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
31. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
33. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
[TBL] [Abstract][Full Text] [Related]
34. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
35. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
[TBL] [Abstract][Full Text] [Related]
36. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Tan YH; Krishnaswamy S; Nandi S; Kanteti R; Vora S; Onel K; Hasina R; Lo FY; El-Hashani E; Cervantes G; Robinson M; Hsu HS; Kales SC; Lipkowitz S; Karrison T; Sattler M; Vokes EE; Wang YC; Salgia R
PLoS One; 2010 Jan; 5(1):e8972. PubMed ID: 20126411
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
38. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
39. Acquired
Li A; Yang JJ; Zhang XC; Zhang Z; Su J; Gou LY; Bai Y; Zhou Q; Yang Z; Han-Zhang H; Zhong WZ; Chuai S; Zhang Q; Xie Z; Gao H; Chen H; Wang Z; Wang Z; Yang XN; Wang BC; Gan B; Chen ZH; Jiang BY; Wu SP; Liu SY; Xu CR; Wu YL
Clin Cancer Res; 2017 Aug; 23(16):4929-4937. PubMed ID: 28396313
[No Abstract] [Full Text] [Related]
40. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]